Neoadjuvant therapy combo for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of head and neck squamous cell carcinoma that can be removed by surgery and hasn't spread to other parts of the body.
- Your cancer is either HPV-positive stage III (with a large tumor) or HPV-negative stage III/IVA, or stage III/IVA of the larynx, hypopharynx, or oral cavity, and your PD-L1 combined positive score is 1 or higher.
- You are 18 years or older.
- You have adequate organ function (bone marrow, liver, kidneys) as shown by blood tests.
- You are willing to provide a tissue sample (either from a previous biopsy or a new one) and allow use of leftover tissue from surgery for research.
- If female, you are either surgically sterile, postmenopausal, or using highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.